In biotech, your slide deck isn’t just a formality – it’s your first business case.At Liberi Group, we’ve reviewed and refined hundreds of decks over the years, across investor pitches, pharma partnering, and BD outreach. The patterns are clear: strong materials open doors, weak ones close them. These do’s and don’ts draw on real-world experience to help you present your story clearly, credibly, and strategically.

In biotech, “AI” has officially joined the ranks of overused buzzwords – right up there with “platform” and “transformative.” And here’s the thing: if you’re using the label without meaningful substance – Are you adding real value or raising red flags?  At Liberi, we talk to investors and BD leaders across the globe, and the message is clear: AI is no longer impressive by default. If your deck mentions machine learning or neural networks but your product is a glorified dashboard, you’re not differentiating – you’re diluting.

The therapeutic antibody space is entering a new era. Following the success of monoclonal and bi-specific antibodies, tri-specific antibodies (TsAbs) are emerging as a powerful innovation. These engineered biologics bind to three distinct targets at once, offering unprecedented precision, particularly in immuno-oncology.¹